Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab.
Bureau M, Chatellier T, Perennec T, Goronflot T, Greilsamer C, Chene AL, Affi R, Frampas E, Bennouna J, Pons-Tostivint E. Bureau M, et al. Cancer Immunol Immunother. 2022 Jul;71(7):1747-1756. doi: 10.1007/s00262-021-03108-x. Epub 2021 Nov 28. Cancer Immunol Immunother. 2022. PMID: 34839373 Free PMC article.
Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
Pons-Tostivint E, Hulo P, Guardiolle V, Bodot L, Rabeau A, Porte M, Hiret S, Demontrond P, Curcio H, Boudoussier A, Veillon R, Mayenga M, Dumenil C, Chatellier T, Gourraud PA, Mazieres J, Bennouna J. Pons-Tostivint E, et al. Cancer Immunol Immunother. 2023 Jun;72(6):1881-1890. doi: 10.1007/s00262-022-03359-2. Epub 2023 Jan 24. Cancer Immunol Immunother. 2023. PMID: 36690799 Free PMC article.
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
Pons-Tostivint E, Hulo P, Guardiolle V, Bodot L, Rabeau A, Porte M, Hiret S, Demontrond P, Curcio H, Boudoussier A, Veillon R, Mayenga M, Dumenil C, Chatellier T, Gourraud PA, Mazieres J, Bennouna J. Pons-Tostivint E, et al. Cancer Immunol Immunother. 2023 Jun;72(6):1891-1892. doi: 10.1007/s00262-023-03405-7. Cancer Immunol Immunother. 2023. PMID: 36847863 Free PMC article. No abstract available.
35 results